# Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

> **NCT06731413** · PHASE2 · RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 40 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- NSCLC
- Advanced Non-Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Reduced Dose of Chemotherapy and Immunotherapy

## Key facts

- **NCT ID:** NCT06731413
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-11
- **Primary completion:** 2030-07-30
- **Final completion:** 2033-07-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731413, "Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06731413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*